Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies

ABSTRACT: A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies

PROVIDER: PRJNA607546 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11113538_1.fastq.gz	Fastqsanger.gz
	SRR11113538_2.fastq.gz	Fastqsanger.gz
	SRR11113539_1.fastq.gz	Fastqsanger.gz
	SRR11113539_2.fastq.gz	Fastqsanger.gz
	SRR11113540_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 42

Similar Datasets

A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies (WES)

Project description:A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies (WES)

| PRJNA607549 | ENA

A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies (RNA-Seq)

Project description:A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies (RNA-Seq)

| PRJNA607547 | ENA

A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies (WES)

Project description:Glioblastomas are the most lethal tumors affecting the central nervous system in adults. Simple and inexpensive syngeneic in vivo models that closely mirror human glioblastoma, including interactions between tumor and immune cells, are urgently needed for deciphering glioma biology and developing more effective treatments. Here, we generated mouse glioblastoma cell lines by repeated in-vivo passaging of neural stem cells and tumor tissue of a neural stem cell-specific Pten/p53 double-knockout genetic mouse model. Transcriptome and genome analyses of the cell lines revealed molecular heterogeneity comparable to that observed in human glioblastoma. Upon orthotopic transplantation into syngeneic hosts they formed high-grade gliomas that faithfully recapitulated the histopathological characteristics, invasiveness and infiltration by myeloid cells characteristic of human glioblastoma. These features make our cell lines unique and useful tools to study multiple aspects of glioma pathomechanism and test immunotherapies in syngeneic preclinical models.

2021-01-27 | GSE145558 | GEO

A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies (RNA-Seq)

2021-01-27 | GSE145557 | GEO

A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studies

Project description:This SuperSeries is composed of the SubSeries listed below.

2021-01-27 | GSE145559 | GEO

Targeting tumor-intrinsic neural vulnerabilities of glioblastoma

Project description:The neural behavior of glioblastoma, including the formation of tumor microtubes and synaptic circuitry, is increasingly understood to be pivotal for disease manifestation (Osswald et al. 2015; Venkatesh et al. 2015; Weil et al. 2017; Venkataramani et al. 2019; Venkatesh et al. 2019; Alcantara Llaguno et al. 2019; Venkataramani et al. 2022). Nonetheless, the few approved treatments for glioblastoma target its oncological nature, while its neural vulnerabilities remain incompletely mapped and clinically unexploited. Here, we systematically survey the neural molecular dependencies and cellular heterogeneity across 27 glioblastoma patients and diverse model systems. In patient tumor samples taken directly after surgery, we identify a spectrum of neural stem cell morphologies indicative of poor prognosis, and discover a set of repurposable neuroactive drugs with unexpected and consistent anti-glioma efficacy. Glioblastoma cells exhibit functional dependencies on highly expressed drug targets including neurological ion channels and receptors, while interpretable molecular machine learning reveals downstream convergence on secondary drug targets (COSTAR) involving AP-1-driven tumor suppression. COSTAR enables in silico drug screening on >1 million compounds that are validated with high accuracy. Multi-omic profiling of drug-treated glioblastoma cells confirms rapid Ca2+-driven AP-1 pathway induction to represent a tumor-intrinsic vulnerability at the intersection of oncogenesis and neural activity-dependent signaling. Finally, the consistent anti-glioma activity across patients and model systems is epitomized by the antidepressant Vortioxetine, which synergizes in vivo with approved glioblastoma chemotherapies. In all, our global analysis reveals that the neural vulnerabilities of glioblastoma converge on an AP-1 mediated gene regulatory network with direct translatable potential.

2024-08-01 | PXD037015 | panorama

Expression profiling of normal and glioblastoma-derived neural stem cells

Project description:Exon array analysis of glioblastoma-derived neural stem (GNS) cells performed in parallel with normal neural stem (NS) cell lines

2015-10-01 | E-MTAB-3864 | biostudies-arrayexpress

MicroRNA expression profiling of normal and glioblastoma-derived neural stem cells

Project description:MicroRNA analysis of glioblastoma-derived neural stem (GNS) cells performed in parallel with normal neural stem (NS) cell lines

2016-11-01 | E-MTAB-3865 | biostudies-arrayexpress

Expression profiling of glioblastoma neural stem cells and reprogrammed derivatives

Project description:Glioblastoma-derived neural stem (GNS) cells were reprogrammed to induced pluripotent stem (iPS) cells by transgenic expression of OCT4 and KLF4. Gene expression profiling was performed in comparison to normal neural stem (NS) cells reprogrammed in parallel, as well as standard ES cells as an independent reference.

2013-03-15 | E-MTAB-1273 | biostudies-arrayexpress

Methylation profiling of glioblastoma neural stem cells and reprogrammed derivatives

Project description:Glioblastoma-derived neural stem (GNS) cells were reprogrammed to induced pluripotent stem (iPS) cells by transgenic expression of OCT4 and KLF4. Genome-wide DNA methylation status was profiled at 27,578 CpG sites to assess epigenetic erasure and restoration due to reprogramming and redifferentiation to the neural stem (NS) cell state.

2013-03-15 | E-MTAB-1275 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data